无进展生存期作为初治弥漫大B细胞淋巴瘤总生存期的替代终点:多项随机试验的个体患者水平分析(SEAL)
该研究纳入13项多中心随机对照试验共7,507例初治弥漫大B细胞淋巴瘤患者,采用线性回归(R2WLS)和Copula双变量模型(R2Copula)在试验水平评估PFS与PFS24对OS的替代性。PFS的替代性强度为R2WLS=0.83、R2Copula=0.85,达到预设替代标准;PFS24为R2WLS=0.77、R2Copula=0.78,未达到预设标准。
要点
- PFS在试验水平对OS的替代性强度为R2WLS=0.83、R2Copula=0.85,达到预设替代标准。
- PFS24的替代性为R2WLS=0.77、R2Copula=0.78,未达到预设替代标准。
- PFS的替代阈值效应风险比为0.89,PFS24的替代阈值效应比值比为1.51。
核心结论
- 这项大型个体患者数据汇总分析支持将PFS作为未来评估弥漫大B细胞淋巴瘤化学免疫治疗的随机对照试验中OS的替代终点。
- 使用该终点可能加速治疗开发,以期在OS结果成熟前数年将新疗法带给该患者群体。
研究设计与样本
- 研究分析了2002年以后发表的13项多中心随机对照试验中7,507例既往未经治疗的弥漫大B细胞淋巴瘤接受积极治疗患者的个体患者数据,这些试验具有足够的PFS数据以预测治疗对OS的效应。
- 采用线性回归(R2WLS)和Copula双变量模型(R2Copula)评估PFS与PFS24的治疗效应估计值与OS治疗效应估计值的相关性,以进行试验水平替代性分析。
- 预设替代标准要求R2WLS或R2Copula≥0.80且两者均不低于0.7,同时95%CI下限>0.60。
主要发现
- PFS的试验水平替代性强(R2WLS=0.83;R2Copula=0.85),达到预设替代标准。
- 在患者水平,PFS与OS强相关;PFS的替代阈值效应风险比为0.89。
- PFS的替代性在含或不含利妥昔单抗的比较以及利妥昔单抗维持治疗试验中保持一致。
- PFS24的试验水平替代性相对较强(R2WLS=0.77;R2Copula=0.78),但未达到预设标准。
- 在患者水平,PFS24与OS显著相关;PFS24的替代阈值效应比值比为1.51。
关键数值与推荐
- 预设替代标准:R2WLS或R2Copula≥0.80且两者均不低于0.7,95%CI下限>0.60。
- PFS达到预设替代标准:R2WLS=0.83,R2Copula=0.85。
- PFS24未达到预设替代标准:R2WLS=0.77,R2Copula=0.78。
- PFS的替代阈值效应风险比为0.89;PFS24的替代阈值效应比值比为1.51。
临床怎么用
- 作者认为,PFS可作为未来评估弥漫大B细胞淋巴瘤化学免疫治疗的随机对照试验中OS的替代终点。
- 作者认为,使用该终点可能加速治疗开发,以期在OS结果成熟前数年将新疗法带给该患者群体。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Overall survival (OS) is the definitive and best-established primary efficacy end point to evaluate diffuse large B-cell lymphoma (DLBCL) therapies, but it requires prolonged follow-up. An earlier end point assessed post-treatment would expedite clinical trial conduct and accelerate patient access to effective new therapies. Our objective was to formally evaluate progression-free survival (PFS) and PFS at 24 months (PFS24) as surrogate end points for OS in first-line DLBCL. Patients and Methods Individual patient data were analyzed from 7,507 patients from 13 multicenter randomized controlled trials of active treatment in previously untreated DLBCL, published after 2002, with sufficient PFS data to predict treatment effects on OS. Trial-level surrogacy examining the correlation of treatment effect estimates of PFS/PFS24 and OS was evaluated using both linear regression ( R2WLS) and Copula bivariable ( R2Copula) models. Prespecified criteria for surrogacy required either R2WLS or R2Copula ≥ 0.80 and neither < 0.7, with lower-bound 95% CI > 0.60. Results Trial-level surrogacy for PFS was strong ( R2WLS = 0.83; R2Copula = 0.85) and met the predefined criteria for surrogacy. At the patient level, PFS strongly correlated with OS. The surrogate threshold effect had a hazard ratio of 0.89. Surrogacy was consistent across comparisons with or without rituximab and with rituximab maintenance trials. Trial-level surrogacy for PFS24 was relatively strong ( R2WLS = 0.77; R2Copula = 0.78) but did not meet prespecified criteria. At the patient level, PFS24 significantly correlated with OS. The surrogate threshold effect had an odds ratio of 1.51. Conclusion This large pooled analysis of individual patient data supports PFS as a surrogate end point for OS in future randomized controlled trials evaluating chemoimmunotherapy in DLBCL. Use of this end point may expedite therapeutic development with the intent of bringing novel therapies to this patient population years before OS results are mature.
引用
- Shi Q, Schmitz N, Ou FS, et al. Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL). J Clin Oncol. 2018. PMID: 29975624. doi:10.1200/JCO.2018.77.9124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。